4 Results for: created: (03/2018 to 03/2018)

People

  1. Motzer
    Motzer
  2. Voss
    Voss
  3. Arcila
    Arcila
  4. Becerra
    Becerra
  5. Benfante
    Benfante
  6. Casuscelli
    Casuscelli
  7. Coleman
    Coleman
  8. Djesevic
    Djesevic
  9. Feldman
    Feldman
  10. Hakimi
    Hakimi

Groups

  1. Department of Medicine (4)
  2. Genitourinary Oncology Service (4)
  3. Solid Tumor Oncology Division (4)
  4. Department of Pathology and Laboratory Medicine (1)
  5. Human Oncology and Pathogenesis Program (1)
  6. Sloan Kettering Institute Postdocs (1)
  7. Surgery (1)
  8. Survivorship Research (1)
  9. Thoracic Oncology (1)
  10. Urology (1)
  1. "Robert Motzer"
Formats
  1. Journal Article (4)
Groups
  1. Department of Medicine (4)
  2. Genitourinary Oncology Service (4)
  3. Solid Tumor Oncology Division (4)
  4. Department of Pathology and Laboratory Medicine (1)
  5. Human Oncology and Pathogenesis Program (1)
  6. Sloan Kettering Institute Postdocs (1)

More Groups

People
  1. Robert Motzer (4)
  2. Martin Voss (2)
  3. Abraham Hakimi (1)
  4. Alexandra Snyder Charen (1)
  5. Almedina Djesevic (1)
  6. Brandon Manley (1)

More People

Years
  1. 2018 (3)
  2. 2017 (1)
Publications
  1. BMC Cancer (1)
  2. European Urology (1)
  3. European Urology Focus (1)
  4. Science (1)
Publishers
  1. American Association for the Advancement of Science (1)
  2. Biomed Central Ltd (1)
  3. Elsevier B.V. (1)
  4. Elsevier Science, Inc. (1)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
    Journal Article

    Miao, D.; Margolis, C. A.; Gao, W.; Voss, M. H.; Li, W.; Martini, D. J.; Norton, C.; Bossé, D.; Wankowicz, S. M.; Cullen, D.; more...
    Science (2018)

    Fulltext@MSK | Save
  • Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's letter to the editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: Subgroup analyses and updated overall survival results. Eur Urol 2018;73:62–8
    Journal Article

    Motzer, R. J.; Escudier, B.; Ravaud, A.
    European Urology (2018)

    Fulltext@MSK | Save
  • RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
    Journal Article

    Yang, L.; Alyasova, A.; Ye, D.; Ridolfi, A.; Dezzani, L.; Motzer, R. J.
    BMC Cancer (2018)

    Fulltext@MSK | Save
  • Integration of recurrent somatic mutations with clinical outcomes: A pooled analysis of 1049 patients with clear cell renal cell carcinoma
    Journal Article

    Manley, B. J.; Zabor, E. C.; Casuscelli, J.; Tennenbaum, D. M.; Redzematovic, A.; Becerra, M. F.; Benfante, N.; Sato, Y.; Morikawa, T.; Kume, H.; more...
    European Urology Focus (2017)

    Fulltext@MSK | Save